DeepMed Research

Shanghai SIMR Biotechnology Co.,Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

The Pharmacokinetics (PK), Safety, Tolerability of SR750 (Prescription F1) in Healthy Volunteers

Phase 1

Not yet recruiting

Conditions: Healthy

Interventions: Drug: SR750 tablet
Drug: Placebo

First Posted Date: 2025-04-17

Last Posted Date: 2025-04-25

Lead Sponsor: Shanghai SIMR Biotechnology Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT06932536

Locations: 🇨🇳
Shanghai Clinical Research Center Phase I Clinical Research Unit (SCRC-PCRU), Shanghai, Shanghai, China

Efficacy and Safety of SR1375 in Adult Patients With CAP

Phase 2

Recruiting

Conditions: Community-acquired Pneumonia

Interventions: Drug: SR1375 capsule 3mg+regular treatments
Drug: SR1375 capsule 1mg+regular treatments
Drug: SR1375 capsule 0.3mg+regular treatments
Drug: Placebo capsule+regular treatments

First Posted Date: 2024-08-29

Last Posted Date: 2025-04-09

Lead Sponsor: Shanghai SIMR Biotechnology Co., Ltd.

Target Recruit Count: 240

Registration Number: NCT06577558

Locations: 🇨🇳
Fuyang People's Hospital, Fuyang, Anhui, China
🇨🇳
Zhangzhou Hospital, Zhangzhou, Fujian, China
🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

and more 23 locations

Efficacy, Safety, and Tolerability of SR750 in Patients With Trigeminal Neuralgia

Phase 2

Not yet recruiting

Conditions: Trigeminal Neuralgia

Interventions: Drug: SR750 tablet
Drug: Placebo

First Posted Date: 2024-08-26

Last Posted Date: 2024-08-26

Lead Sponsor: Shanghai SIMR Biotechnology Co., Ltd.

Target Recruit Count: 162

Registration Number: NCT06571448

The Pharmacokinetics (PK), Safety, Tolerability of SR750 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: SR750 tablet
Drug: Placebo

First Posted Date: 2023-03-03

Last Posted Date: 2024-11-28

Lead Sponsor: Shanghai SIMR Biotechnology Co., Ltd.

Target Recruit Count: 56

Registration Number: NCT05753033

Locations: 🇨🇳
Shanghai Clinical Research Center Phase I Clinical Research Unit (SCRC-PCRU), Shanghai, China

The Pharmacokinetics (PK), Pharmacodynamics(PD), Safety, Tolerability of SR1375 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: SR1375 capsules
Other: Placebo

First Posted Date: 2022-06-16

Last Posted Date: 2024-11-28

Lead Sponsor: Shanghai SIMR Biotechnology Co., Ltd.

Target Recruit Count: 32

Registration Number: NCT05421923

Locations: 🇨🇳
Phase I clinical laboratory of Huashan Hospital, Shanghai, China

To Evaluate the Efficacy and Safety of SR419 in Patients With Postherpetic Neuralgia (PHN)

Phase 2

Completed

Conditions: Postherpetic Neuralgia

Interventions: Drug: SR419

First Posted Date: 2022-05-03

Last Posted Date: 2024-01-05

Lead Sponsor: Shanghai SIMR Biotechnology Co., Ltd.

Target Recruit Count: 83

Registration Number: NCT05357677

Locations: 🇦🇺
PARATUS Clinical Research Brisbane, Brisbane, Australia
🇨🇳
Peking University Third Hospital, Beijing, China
🇦🇺
Genesis Research Services, Sydney, Australia

and more 10 locations

The Safety, Tolerability, and Pharmacokinetics (PK) of SR750 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: matching placebo
Drug: SR750 tablet

First Posted Date: 2021-10-19

Last Posted Date: 2024-11-29

Lead Sponsor: Shanghai SIMR Biotechnology Co., Ltd.

Target Recruit Count: 83

Registration Number: NCT05083468

Locations: 🇦🇺
Nucleus Network Pty Ltd, Melbourne, Victoria, Australia

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SR1375

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: SR1375
Drug: Matching placebo

First Posted Date: 2021-08-30

Last Posted Date: 2024-11-29

Lead Sponsor: Shanghai SIMR Biotechnology Co., Ltd.

Target Recruit Count: 72

Registration Number: NCT05026008

Locations: 🇦🇺
Linear Clinical Research Ltd, Nedlands, Western Australia, Australia

The Pharmacokinetics (PK), Safety, Tolerability of SR419 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: SR419 capsules

First Posted Date: 2021-08-19

Last Posted Date: 2024-11-28

Lead Sponsor: Shanghai SIMR Biotechnology Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT05012761

Locations: 🇨🇳
Shanghai Clinical Research Center Phase I Clinical Research Unit (SCRC-PCRU), Shanghai, China

A Phase 1b Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SR419

Phase 1

Completed

Conditions: Peripheral Neuropathic Pain

Interventions: Drug: SR419
Drug: active control
Drug: active control placebo
Drug: SR419 placebo

First Posted Date: 2020-07-31

Last Posted Date: 2024-11-28

Lead Sponsor: Shanghai SIMR Biotechnology Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT04494815

Locations: 🇦🇺
Clinical Research Facility Medical School, University of Adelaide, Adelaide, South Australia, Australia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy